Piracetam 800mg Tablets

Each Film coated Tablet contains
Piracetam BP………………..800mg
Excipients Q.S.

Drug form and composition:
Solution for injection. One ampoule of 5 ml contains 1 g Piracetam (200 mg/ml). Film-coated tablets. One tablet contains 400 mg of Piracetam.

Indications:
Piracetam, solution for injection is used in cases of severe brain diseases: cerebro-cranial trauma in acute stage, comatose states, ischemic stroke, acute psychic disturbances due to intoxications, alcohol delirium. Piracetam tablets are used in cerebro-vascular disease; degenerative cortical dementia (Alzheimer’s disease); senile psychoorganic syndrome ("aging brain"); cortical myoclonia; dyslexia of vascular and other origin; vestibulopathies; protection of the nervous tissue in a brain hypoxia; postoperative deliriums.

Dosage and administration:
Adults: Parenteral administration. The drug is administered intramuscularly, as a drop intravenous or as a slow intravenous infusion. The recommended 24-hours dose is 3 - 12 g (depending on the severity of the disease) which should be divided in 2-4 takes. Oral administration. Starting dose - 800 mg (2 tablets), 3 times daily. After the desired effect has been achieved the dose can be reduced to 400 mg (1 tablet), 3 times daily. Children: 400 mg 2 or 3 times daily. Administration of the drug after 04:00 h P.M. should be avoided because of its exciting action and the possibility of disturbing the night sleep of the patient. The duration of the treatment course is 2 - 3 months, but in severe cases the drug can be used for a period of 6 - 12 months.

Contraindications
First trimester of pregnancy; severe parenchymal liver or kidney diseases; agitated depression, particularly in the elderly.

Special warnings and precautions:
In patients suffering from liver diseases, a monitoring of the liver enzymes and function is necessary. In patients with renal failure, the 24-hours dose should be adjusted according to the creatinine clearance. The levels of the residual nitrogen and creatinine should be checked regularly. Because of the distribution into breast milk the breast-feeding should be discontinued for the period of the treatment.

Drug interactions:
Piracetam increases the effects of the drugs stimulating the CNS, thyroid hormones and oral anticoagulants. The concurrent administration of neuroleptics increases the risk of hyperkinesia.

Adverse reactions:
Rarely in susceptible patients can be observed the following symptoms: increased aggressiveness, headache, sleep disturbance, gastrointestinal problems, blood pressure instability.

Note: This website contains medical information that is intended for doctors or medical practitioner only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Privacy Policy and Terms of Use. © Copyright 2012. Taj Pharma Group (India). All rights reserved.
Pharmacological mechanisms:

Piracetam is a nootropic agent. It improves the metabolic processes in the brain cells, possesses an antihypoxic action, accelerates the reparative processes in functionally damaged cells after traumas, intoxications, and stoke. Piracetam acts selectively on the telencephalon, improving its associative functions. The drug has an antiplatelet and a microcirculation ameliorating action. The therapeutic effect of Piracetam is manifested after prolonged treatment (several weeks to several months).

For Information about Generic Medicines: genericmedicines@taipharma.com

Note: This product information is intended only for residents of the India. Taj Pharmaceuticals Limited, medicines help to treat and prevent a range of conditions—from the most common to the most challenging—for people around the world. The Price of the drugs indicated above may not match the actual price at which they are sold. Prices can change depending on many factors, including local taxes. These are only approximate indicative prices of the drug. The products discussed herein may have different product labelling in different countries. The product information provided in this site is intended only for the residents of India.

Information for Health Care Professionals

*** Please consult local Prescribing Information for any product before use. This website is an international information resource for healthcare professionals with an interest in disease management. This website is not intended to replace the advice of a qualified healthcare professional. Above brand is a trademark of the Taj group of companies (Taj Pharmaceuticals Limited).
This document includes statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the fact that they do not only relate to historical or current events. Forward-looking statements often use words such as “anticipate”, “target”, “expect”, “estimate”, “intend”, “expected”, “plan”, “goal” believe”, or other words of similar meaning. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances, a number of which are beyond Company's control. As a result, actual future results may differ materially from the plans, goals and expectations set out in these forward-looking statements. Any forward-looking statements made by or on behalf of the Company speak only as at the date of this announcement. Save as required by any applicable laws or regulations, the Company undertakes no obligation publicly to release the results of any revisions to any forward-looking statements in this document that may occur due to any change in its expectations or to reflect events or circumstances after the date of this document. The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States or to US persons unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. No public offering of the securities will be made in the United States. This communication is being distributed only to and is directed only at (a) persons outside the United Kingdom, (b) persons who have professional experience in matters relating to investments, i.e., investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), and (c) high net worth companies, unincorporated associations and other bodies to whom it may otherwise lawfully be communicated in accordance with Article 49 of the Order (all such persons together being referred to as "relevant persons"). The securities are available only to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be available only to or will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.
About Taj Pharmaceutical Limited

Taj Pharmaceuticals Limited is a pharmaceutical company founded and based in India. The company manufacturers pharmaceutical formulations and API for India and other countries of the world. The company was established in 1995 as an enterprise and in 2004 became a public limited company. As per Mumbai pharmaxil and Chemixil association the company manufacturers and exports to countries like Albania, Argentina, Austria, Chile and Iraq. In 1995 pharmaceuticals wing only has a schedule M certification for pharmaceuticals products manufacturing in India. Taj Pharmaceuticals established its manufacturing unit in Gujarat because of government policies in 1999 with WHO / GMP licence. The company in 2003 revived all the old manufacturing units and approached the FDA Gujarat for 4000 new pharmaceuticals drug permissions for the first time in India.

According to the Indian Trade Mark the company owns about 450 brands and 4600 generic manufacturing permissions in India. According to the export data analysis the company was the largest exporter of generic medicines to the Europe and Middle East countries.

www.tajpharma.com

The company medicines are present in France, Georgia, Egypt and CIF countries.